Results 81 to 90 of about 250 (109)
Some of the next articles are maybe not open access.
SLEEP
Abstract Introduction The Epworth Sleepiness Scale (ESS) is a commonly used 8-item patient-reported outcome measure for excessive daytime sleepiness. While aggregate data are typically presented, individual domains vary in clinical significance.
Heidy Merius +5 more
openaire +1 more source
Abstract Introduction The Epworth Sleepiness Scale (ESS) is a commonly used 8-item patient-reported outcome measure for excessive daytime sleepiness. While aggregate data are typically presented, individual domains vary in clinical significance.
Heidy Merius +5 more
openaire +1 more source
SLEEP
Abstract Introduction Extended-release, once-nightly sodium oxybate (ON-SXB; LUMRYZ™) eliminates the middle-of-the-night dosing required with immediate-release, twice-nightly oxybates (TN-OXBs). RESTORE (NCT04451668) was an open label/switch study that assessed the safety and tolerability of ON-SXB in
Adrian Santamaria +7 more
openaire +1 more source
Abstract Introduction Extended-release, once-nightly sodium oxybate (ON-SXB; LUMRYZ™) eliminates the middle-of-the-night dosing required with immediate-release, twice-nightly oxybates (TN-OXBs). RESTORE (NCT04451668) was an open label/switch study that assessed the safety and tolerability of ON-SXB in
Adrian Santamaria +7 more
openaire +1 more source
SLEEP
Abstract Introduction Once-nightly sodium oxybate (ON-SXB; LUMRYZ™) was investigated in patients with narcolepsy type 1 (NT1) or 2 (NT2) in the phase 3 REST-ON trial; treatment with 6, 7.5, and 9 g demonstrated significant improvements vs placebo (all P< 0.001) for the coprimary endpoints of ...
Michael Thorpy +7 more
openaire +1 more source
Abstract Introduction Once-nightly sodium oxybate (ON-SXB; LUMRYZ™) was investigated in patients with narcolepsy type 1 (NT1) or 2 (NT2) in the phase 3 REST-ON trial; treatment with 6, 7.5, and 9 g demonstrated significant improvements vs placebo (all P< 0.001) for the coprimary endpoints of ...
Michael Thorpy +7 more
openaire +1 more source
SLEEP
Abstract Introduction A novel once-nightly formulation of sodium oxybate (ON-SXB; LUMRYZ™) was investigated in patients with narcolepsy type 1 (NT1) and 2 (NT2) in the phase 3 REST-ON trial (NCT02720744).
Luis Ortiz +7 more
openaire +1 more source
Abstract Introduction A novel once-nightly formulation of sodium oxybate (ON-SXB; LUMRYZ™) was investigated in patients with narcolepsy type 1 (NT1) and 2 (NT2) in the phase 3 REST-ON trial (NCT02720744).
Luis Ortiz +7 more
openaire +1 more source
LONG-TERM SAFETY OF ONCE-NIGHTLY SODIUM OXYBATE: INTERIM ANALYSIS OF DATA FROM RESTORE
Chest, 2022THOMAS P STERN +7 more
openaire +1 more source
SLEEP
Abstract Introduction Once-nightly sodium oxybate (ON-SXB; LUMRYZ™) is approved to treat excessive daytime sleepiness and cataplexy in adult and pediatric patients ≥7 years of age with narcolepsy. The REFRESH study assesses the clinical effectiveness, patient satisfaction, and safety of ON-SXB for the
Sarah Meskill +9 more
openaire +1 more source
Abstract Introduction Once-nightly sodium oxybate (ON-SXB; LUMRYZ™) is approved to treat excessive daytime sleepiness and cataplexy in adult and pediatric patients ≥7 years of age with narcolepsy. The REFRESH study assesses the clinical effectiveness, patient satisfaction, and safety of ON-SXB for the
Sarah Meskill +9 more
openaire +1 more source
SLEEP
Abstract Introduction Once-nightly sodium oxybate (ON-SXB; LUMRYZ™) is an extended-release formulation of sodium oxybate that eliminates the second, middle-of-the-night dose required by immediate-release twice-nightly oxybate (TN-OXB) formulations.
Sally Ibrahim +7 more
openaire +1 more source
Abstract Introduction Once-nightly sodium oxybate (ON-SXB; LUMRYZ™) is an extended-release formulation of sodium oxybate that eliminates the second, middle-of-the-night dose required by immediate-release twice-nightly oxybate (TN-OXB) formulations.
Sally Ibrahim +7 more
openaire +1 more source
Long-Term Safety of Once-Nightly Sodium Oxybate: Interim Analysis of Data From RESTORE (P5-13.005)
Neurology, 2023Thomas Stern +8 more
openaire +1 more source